AGEN (Agenus) שווי פירמה כולל

Agenus (AGEN) is accelerating antibody development using AI, although the final validation of drugs remains with physicians. The company relies on a dedicated staff of scientists, retaining key developers through a stock option system. High R&D and patent costs create a significant barrier to entry, which confirms the asset value on the GURU.Markets platform, as reflected in the pakistan chart, which stands at 564.98.

As the owner of a closed patent portfolio in the field of immuno-oncology, Agenus is valued via Enterprise Value, which combines market capitalization with net debt to determine the total cost of acquiring the business. By analyzing the company's aggregate asset valuation, an investor can discern the actual price for buying out all B2B development rights, where growth in this metric signals an inflow of liquidity, while the debt load indicates systemic risks.